TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
Zhang X, Li S, He J, Jin Y, Zhang R, Dong W, Lin M, Yang Y, Tian T, Zhou Y, Xu Y, Lei QY, Zhang J, Zhang Q, Xu Y, Lv L.
Zhang X, et al. Among authors: he j.
Cancer Res. 2022 Jun 6;82(11):2097-2109. doi: 10.1158/0008-5472.CAN-21-3013.
Cancer Res. 2022.
PMID: 35176127